S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
S&P 500   3,821.35 (-0.54%)
DOW   31,802.44 (+0.97%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals Competitors

$7.88
+0.13 (+1.68 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.60
Now: $7.88
$8.24
50-Day Range
$7.80
MA: $10.35
$11.82
52-Week Range
$4.71
Now: $7.88
$19.47
Volume359,844 shs
Average Volume458,237 shs
Market Capitalization$107.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23

Competitors

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Vs. FIXX, APLT, PBYI, RAPT, ATNX, and ALDX

Should you be buying ATNM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Actinium Pharmaceuticals, including Homology Medicines (FIXX), Applied Therapeutics (APLT), Puma Biotechnology (PBYI), RAPT Therapeutics (RAPT), Athenex (ATNX), and Aldeyra Therapeutics (ALDX).

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Homology Medicines, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
Homology Medicines01702.88

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Homology Medicines has a consensus price target of $28.3750, suggesting a potential upside of 200.58%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Homology Medicines.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Homology Medicines' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
Homology Medicines$1.67 million255.86$-103,920,000.00($2.47)-3.82

Actinium Pharmaceuticals has higher earnings, but lower revenue than Homology Medicines.

Profitability

This table compares Actinium Pharmaceuticals and Homology Medicines' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
Homology Medicines-5,386.00%-57.92%-45.33%

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Homology Medicines beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Applied Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
Applied Therapeutics00303.00

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Applied Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 280.21%. Given Actinium Pharmaceuticals' higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Applied Therapeutics.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Applied Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
Applied TherapeuticsN/AN/A$-45,510,000.00($3.55)-4.67

Profitability

This table compares Actinium Pharmaceuticals and Applied Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
Applied TherapeuticsN/A-85.39%-70.42%

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 54.3% of Applied Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Applied Therapeutics on 5 of the 8 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Puma Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
Puma Biotechnology14102.00

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Puma Biotechnology has a consensus price target of $12.50, suggesting a potential upside of 19.27%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Puma Biotechnology.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Puma Biotechnology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
Puma Biotechnology$272.30 million1.55$-75,600,000.00($1.95)-5.37

Actinium Pharmaceuticals has higher earnings, but lower revenue than Puma Biotechnology.

Profitability

This table compares Actinium Pharmaceuticals and Puma Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
Puma Biotechnology-23.86%-451.50%-22.80%

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Puma Biotechnology shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Puma Biotechnology on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and RAPT Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
RAPT Therapeutics00503.00

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. RAPT Therapeutics has a consensus price target of $40.80, suggesting a potential upside of 137.76%. Given Actinium Pharmaceuticals' higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than RAPT Therapeutics.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and RAPT Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
RAPT TherapeuticsN/AN/A$-43,000,000.00($9.89)-1.74

Profitability

This table compares Actinium Pharmaceuticals and RAPT Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
RAPT TherapeuticsN/A-48.78%-42.35%

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 65.0% of RAPT Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 31.0% of RAPT Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

RAPT Therapeutics beats Actinium Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Athenex (NASDAQ:ATNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Athenex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
Athenex05302.38

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Athenex has a consensus price target of $16.2857, suggesting a potential upside of 261.90%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Athenex.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Athenex's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
Athenex$101.23 million4.15$-123,750,000.00($1.67)-2.69

Actinium Pharmaceuticals has higher earnings, but lower revenue than Athenex.

Profitability

This table compares Actinium Pharmaceuticals and Athenex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
Athenex-75.45%-66.12%-33.81%

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Athenex has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 57.7% of Athenex shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of Athenex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Actinium Pharmaceuticals beats Athenex on 6 of the 11 factors compared between the two stocks.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Insider & Institutional Ownership

17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Actinium Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Actinium Pharmaceuticals00403.00
Aldeyra Therapeutics01902.90

Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Aldeyra Therapeutics has a consensus price target of $26.4444, suggesting a potential upside of 148.07%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Volatility and Risk

Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.

Earnings and Valuation

This table compares Actinium Pharmaceuticals and Aldeyra Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Actinium PharmaceuticalsN/AN/A$-21,900,000.00N/AN/A
Aldeyra TherapeuticsN/AN/A$-60,830,000.00($2.05)-5.20

Profitability

This table compares Actinium Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Actinium PharmaceuticalsN/A-77.96%-64.62%
Aldeyra TherapeuticsN/A-73.73%-52.74%

Summary

Aldeyra Therapeutics beats Actinium Pharmaceuticals on 6 of the 9 factors compared between the two stocks.


Actinium Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Homology Medicines logo
FIXX
Homology Medicines
1.6$9.44+0.2%$427.29 million$1.67 million-3.46Upcoming Earnings
Analyst Report
Gap Down
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.57+8.3%$422.44 millionN/A-3.48Upcoming Earnings
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.48+3.6%$421.90 million$272.30 million-7.33
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$17.16+1.5%$421.36 millionN/A-6.76
Athenex logo
ATNX
Athenex
1.6$4.50+4.0%$420.55 million$101.23 million-3.08Analyst Report
Insider Selling
Gap Down
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$10.66+4.9%$413.82 millionN/A-8.26Upcoming Earnings
DURECT logo
DRRX
DURECT
1.4$2.03+1.0%$412.45 million$29.56 million-40.59Earnings Announcement
Gap Down
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.62+1.1%$407.35 million$28.91 million-6.03
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.35+1.5%$404.68 million$49.65 million-1.90Earnings Announcement
Analyst Revision
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.00+1.3%$404.44 million$111.39 million28.57Upcoming Earnings
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$7.19+10.4%$404.06 million$1.98 million-4.33Earnings Announcement
Analyst Report
Analyst Revision
UroGen Pharma logo
URGN
UroGen Pharma
1.9$19.24+3.3%$402.06 million$20,000.00-3.01News Coverage
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.70+2.4%$399.71 million$6.68 million-4.46Upcoming Earnings
Analyst Revision
XOMA logo
XOMA
XOMA
1.8$35.86+3.0%$395.25 million$18.37 million-32.31Upcoming Earnings
Cue Biopharma logo
CUE
Cue Biopharma
1.3$13.27+1.7%$395.13 million$3.46 million-8.45High Trading Volume
Gap Down
Evolus logo
EOLS
Evolus
1.3$11.19+3.5%$390.81 million$34.92 million-5.51Upcoming Earnings
Gap Down
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.5$11.86+1.3%$387.43 millionN/A-4.12Earnings Announcement
Analyst Report
Verastem logo
VSTM
Verastem
1.5$2.22+0.0%$376.90 million$17.46 million-1.57Upcoming Earnings
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.7$30.34+2.8%$374.94 million$206.55 million-15.25Upcoming Earnings
News Coverage
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.1$14.46+5.4%$374.02 millionN/A-10.95Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.76+6.6%$371.99 million$3.89 million-4.06News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$3.90+5.4%$365.44 million$36.63 million-4.59Upcoming Earnings
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$3.52+0.3%$364.84 million$102.31 million5.25Upcoming Earnings
News Coverage
Athersys logo
ATHX
Athersys
1.3$1.83+1.1%$361.79 million$5.63 million-4.95Analyst Downgrade
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.65+1.7%$359.62 million$57.49 million-6.43
NATR
Nature's Sunshine Products
1.0$17.88+0.2%$351.49 million$362.21 million21.54Upcoming Earnings
Forte Biosciences logo
FBRX
Forte Biosciences
1.6$27.37+2.2%$351.18 million$40,000.00-1.19Upcoming Earnings
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.5$1.02+0.0%$330.39 millionN/A-0.29Increase in Short Interest
Gap Down
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.19+1.3%$328.16 million$16.54 million-2.92Analyst Report
Analyst Revision
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.9$6.34+5.4%$325.41 million$10.64 million-1.69Earnings Announcement
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.71+2.8%$324.46 millionN/A-5.01Upcoming Earnings
Analyst Upgrade
Increase in Short Interest
News Coverage
Immunic logo
IMUX
Immunic
1.5$15.29+2.0%$323.66 millionN/A-5.18Analyst Report
Analyst Revision
Immunome logo
IMNM
Immunome
1.1$30.61+2.5%$322.69 millionN/A0.00Upcoming Earnings
Trevena logo
TRVN
Trevena
1.4$2.05+2.0%$321.91 million$30,000.00-8.91Upcoming Earnings
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.62+2.8%$316.89 million$6.29 million-4.38Upcoming Earnings
Sesen Bio logo
SESN
Sesen Bio
1.2$2.45+1.2%$316.88 millionN/A-5.57Upcoming Earnings
Decrease in Short Interest
Oncorus logo
ONCR
Oncorus
1.6$13.96+1.1%$315.75 millionN/A0.00Upcoming Earnings
iBio logo
IBIO
iBio
1.3$1.45+2.1%$313.21 million$1.64 million0.00
Graybug Vision logo
GRAY
Graybug Vision
2.0$14.75+7.5%$309.44 millionN/A0.00Analyst Revision
News Coverage
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$12.95+0.0%$308.25 million$1.74 million-8.99Insider Selling
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$13.60+0.1%$302.27 millionN/A-5.15Upcoming Earnings
Analyst Report
NXTC
NextCure
1.6$10.97+3.1%$302.26 million$6.35 million-9.71Earnings Announcement
Analyst Upgrade
Analyst Revision
BELLUS Health logo
BLU
BELLUS Health
1.6$3.84+0.0%$300.81 million$30,000.00-6.51Decrease in Short Interest
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.10+1.4%$297.56 millionN/A-4.38
Theratechnologies logo
THTX
Theratechnologies
1.1$3.07+2.3%$288.09 million$63.22 million-9.90Increase in Short Interest
Ampio Pharmaceuticals logo
AMPE
Ampio Pharmaceuticals
1.3$1.47+0.7%$287.58 millionN/A-10.50Earnings Announcement
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.97+2.3%$276.22 millionN/A-4.78Upcoming Earnings
Increase in Short Interest
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.24+1.9%$275.11 million$6.01 million-2.63Earnings Announcement
Decrease in Short Interest
Kamada logo
KMDA
Kamada
1.4$6.08+0.3%$270.68 million$127.19 million12.67
Galera Therapeutics logo
GRTX
Galera Therapeutics
1.6$10.69+4.6%$266.73 millionN/A-3.06Upcoming Earnings
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.